journal article·2020-06-10

Metal–Organic Framework Microsphere Formulation for Pulmonary Administration

Cristina Fernández-Paz, Sara Rojas, Pablo Salcedo-Abraira, Teresa Simón-Yarza, Carmen Remuñán-López, Patricia Horcajada

ACS Applied Materials & Interfaces· Volume 12· Issue 23
Publisher page

Abstract

Although nanoscaled metal–organic frameworks (nanoMOFs) are promising drug carriers, their appropriate formulation remains almost unexplored and basically restricted to intravenous routes. Lungs, beneficiating from a large absorption surface and low enzymatic presence, are a very attractive target for both local and systemic delivery. However, pulmonary nanoMOF formulation is a pending and defying task. Thus, we propose a pioneer nanoMOF-based microsphere system as a potential platform for pulmonary administration. A biocompatible nanoMOF was successfully encapsulated in mannitol by a simple and continuous spray-drying technique. Upon intratracheal administration to rats, the resulting formulation, exhibiting optimal properties (i.e., homogeneity, size, density, and spray-drying process yield), was able to release the intact nanoMOF carrier uniformly along the lungs, reaching the bronchioles and alveoli.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Metal-Organic Frameworks: Synthesis and Applications · Gas Sensing Nanomaterials and Sensors

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanobiofar Group, Department of Pharmacology, Pharmacy & Pharmaceutical Technology. Faculty of Pharmacy, University of Santiago de Compostela, Campus Vida, 15782 Santiago de Compostela, Spain

Advanced Porous Materials Unit, IMDEA Energy. Av. Ramón de la Sagra 3, 28935 Móstoles-Madrid, Spain

INSERM U1148. Laboratory for Vascular Translational Science, Bichat Hospital, Université de Paris. 75018 Paris, France

Funding

Comunidad de Madrid · Ministerio de Econom?a, Industria y Competitividad, Gobierno de Espa?a · Fundaci?n Ram?n Areces · Xunta de Galicia

References (53)

Show source-provided references
1. 10.1046/j.1365-2125.2003.01892.x10.1046/j.1365-2125.2003.01892.x ↗
2. 10.2147/MDER.S4888810.2147/MDER.S48888 ↗
3. 10.22159/ajpcr.2018.v11i4.2411710.22159/ajpcr.2018.v11i4.24117 ↗
4. Newhouse M. T · CMAJ · 1999 · 161 · 1287
5. Javadzadeh Y. · 2017 · 61910.1016/B978-0-323-46143-6.00020-8 ↗
6. 10.1016/j.jconrel.2015.07.02410.1016/j.jconrel.2015.07.024 ↗
7. 10.1016/j.drudis.2014.09.02010.1016/j.drudis.2014.09.020 ↗
8. 10.1016/j.ijpharm.2014.12.00910.1016/j.ijpharm.2014.12.009 ↗
9. 10.1038/4624810.1038/46248 ↗
10. 10.1021/acs.accounts.7b0009010.1021/acs.accounts.7b00090 ↗
11. 10.1002/adma.20170736510.1002/adma.201707365 ↗
12. 10.1177/204589321771022410.1177/2045893217710224 ↗
13. 10.1021/acsami.8b2022210.1021/acsami.8b20222 ↗
14. 10.1038/nmat260810.1038/nmat2608 ↗
15. 10.1038/srep4309910.1038/srep43099 ↗
16. 10.1039/c3sc22116d10.1039/c3sc22116d ↗
17. 10.1039/c5tb01223f10.1039/c5tb01223f ↗
18. Wimmer T. · 2012 · 267
19. FDA. Inactive Ingredients Search for Approved Drug Products, 2020.
20. WHO. World Health Organization Model List of Essential Medicines, 2019.
21. 10.1016/j.powtec.2011.06.02410.1016/j.powtec.2011.06.024 ↗
22. Raghu G. · 2018
23. Moreno Raja M. · 2019 · 55710.1016/B978-0-12-814033-8.00018-7 ↗
24. 10.1016/j.ijpharm.2010.03.01710.1016/j.ijpharm.2010.03.017 ↗
25. FDA. Inactive Ingredients Database Download File, 2019.
26. 10.1039/c4ra02861a10.1039/c4ra02861a ↗
27. 10.1021/la501255510.1021/la5012555 ↗
28. 10.3390/scipharm8704003310.3390/scipharm87040033 ↗
29. 10.1016/0021-9673(94)80333-110.1016/0021-9673(94)80333-1 ↗
30. Taylor G. · 2001 · 270
31. 10.1615/critrevtherdrugcarriersyst.v19.i45.4010.1615/critrevtherdrugcarriersyst.v19.i45.40 ↗
32. 10.1016/j.ejps.2005.04.00910.1016/j.ejps.2005.04.009 ↗
33. 10.1021/acs.molpharmaceut.7b0016910.1021/acs.molpharmaceut.7b00169 ↗
34. 10.1021/la802405p10.1021/la802405p ↗
35. 10.2147/DDDT.S4768110.2147/DDDT.S47681 ↗
36. 10.3390/ijms1504585210.3390/ijms15045852 ↗
37. 10.1016/j.ijpharm.2016.09.02510.1016/j.ijpharm.2016.09.025 ↗
38. 10.1016/j.jconrel.2011.08.00810.1016/j.jconrel.2011.08.008 ↗
39. 10.1208/s12248-012-9345-610.1208/s12248-012-9345-6 ↗
40. 10.1039/c2cs15327k10.1039/c2cs15327k ↗
41. 10.1038/s41598-018-21378-x10.1038/s41598-018-21378-x ↗
42. 10.1021/jm901858n10.1021/jm901858n ↗
43. 10.2147/copd.s17504710.2147/copd.s175047 ↗
44. 10.1186/1465-9921-11-14910.1186/1465-9921-11-149 ↗
45. 10.4155/tde.14.310.4155/tde.14.3 ↗
46. 10.2174/138161282266616012814535610.2174/1381612822666160128145356 ↗
47. 10.1016/s0168-3659(99)00048-610.1016/s0168-3659(99)00048-6 ↗
48. 10.1513/pats.200409-049ta10.1513/pats.200409-049ta ↗
49. Larrañaga M. D. · 201610.1002/9781119312468 ↗
50. Global TB Report; WHO, 2019.
51. 10.1038/nrmicro320010.1038/nrmicro3200 ↗
52. 10.3390/pharmaceutics1112068710.3390/pharmaceutics11120687 ↗
53. 10.1016/j.bjid.2013.12.00410.1016/j.bjid.2013.12.004 ↗